Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer

2.1 Darolutamide (Nubeqa, Bayer) is indicated for 'the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel'.

2.2 The dosage schedule is available in the summary of product characteristics for darolutamide.

2.3 The list price of darolutamide is £4,040.00 for a 28‑day supply of 112 tablets, each containing 300 mg (excluding VAT, BNF online accessed March 2023).

2.4 The company has a commercial arrangement. This makes darolutamide available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.